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Cell culturea b s t r a c t
Several diseases are related to retinal ganglion cell death, such as glaucoma, diabetes and other retinop-
athies. Many studies have attempted to identify factors that could increase neuroprotection after axot-
omy of these cells. Interleukin-6 has been shown to be able to increase the survival and regeneration
of retinal ganglion cells (RGC) in mixed culture as well as in vivo. In this work we show that the trophic
effect of IL-6 is mediated by adenosine receptor (A2aR) activation and also by the presence of extracel-
lular BDNF. We also show that there is a complex cross-talk between IL-6, BDNF, the Adenosine A1
and A2a receptors that results in neuroprotection of retinal ganglion cells.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Retinal ganglion cell death is observed in diseases such as glau-
coma, diabetes and ischemia [1–3] that cause blindness. It is there-
fore important to study the mechanisms involved in RGC survival
to establish new appropriate pharmacological approaches to treat
the different diseases related to RGC death.
In the past few years there has been considerable interest in the
contribution of cytokines to neuroprotection. Although constitu-
tive levels of cytokines in the brain are low, their production
increases in response to neurotoxic and injury stimuli. One of cyto-
kines that has been the subject of several studies is interleukin-6
(IL-6) [4–6]. Its effects in treatments are still subject to disagree-
ment. Some authors relate IL-6 as a pro-inﬂammatory cytokine
important in several brain pathologies, others have shown that
IL-6 protects neurons in culture and is beneﬁcial in several neuro-
degenerative diseases [4–6]. To date the effect of IL-6 in the brain
and the events that could lead to cell death or to neuroprotection
remain unclear.
IL-6 is produced by T-helper cells (Th1 and Th2), B cells,
macrophages, astrocytes, ﬁbroblasts, osteoblasts, keratinocytes,
endothelial and mesangial cells [7]. In the central nervous system
(CNS) it is synthesized mainly by microglial cells and astrocytes,but also by neurons [8,9]. IL-6 synthesis can be induced by a vari-
ety of stimuli, but its major inducers are lipopolysaccharides (LPS),
interleukin-1 (IL-1) and tumour necrosis factor (TNF) [10].
The IL-6 effects occur through a speciﬁc binding protein, aIL-6R,
that induces the homodimerization of gp130 subunits followed by
the activation of cytoplasmic kinases of the Janus (JAK) family. The
activation of JAKs then leads to the stimulation of proteins from the
STAT family (STAT3 and STAT1) – a family of signal transducers
and transcriptor activators. STAT dimers translocate into the
nucleus and induce transcription of immediate early genes, such
as junB, and the rapid activation of a nuclear factor called acute-
phase response factor (APRF) [5,11].
Previous work from our laboratory demonstrated the trophic
effect of IL-6 on axotomized rat retinal ganglion cells (RGC) kept
in culture for 48 h [12]. More recently we showed that IL-6
treatment induced RGC survival depending on the adenosine A1
receptors (A1R) activation and that a transient levels of extracellu-
lar BDNF was also important for the IL-6 trophic effect [13]. Studies
in vivo showed that IL-6 expression increases in retina after injury,
suggesting its possible neuroprotective role [1]. Sappington and
co-workers have shown that IL-6 also protects RGC from an
increase in intraocular pressure, a condition associated to
glaucoma [2].
Adenosine is a purine nucleoside that regulates processes such
as blood pressure, vasodilatation, neurotransmitter release, neuro-
nal survival and differentiation [14,15]. There are four identiﬁed
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receptors can regulate cAMP production by the activation or the
inhibition of adenylyl cyclase. The activation of A1 and A3 adeno-
sine receptors inhibits adenylyl cyclase activity, while A2a and A2b
stimulate it [16].
Data from literature show that the inhibitionof neurotransmitter
release by A1 adenosine receptor activation appears to be mediated
by the blockade of Ca2+ channels or by the activation of K+ channels
[17–19]. Someauthors alsodemonstrated thatA2aadenosine recep-
tor activity induces neuroprotection and facilitates the release of
neurotransmitter [20,21].
Adenosine has also been described as a modulator of the inﬂam-
matory responses by regulating the balancebetween the production
of pro-inﬂammatory and anti-inﬂammatory cytokines [22]. The
extracellular presence of adenosine depends on either the amount
of adenosine synthesized in the extracellular compartment or the
release of adenosine from the intracellular compartment [23].
It has been shown that adenosine is able to stimulate IL-6
release in different tissues [24–26]. In astrocytes IL-6 can upregu-
late mRNA expression of A1R increasing accumulation of phospha-
tidylinositol, which also happened in a different study, when A1R
was directly activated. The authors showed that adenosine can
stimulate IL-6 release in hypoxic conditions increasing A1 receptor
activity [27–29].
During the studies about the involvement of A1R on IL-6 effect
[13] we found that cAMP production was important to IL-6 effect.
Since A1R is classically involved in the adenylyl cyclase inhibition
and therefore decreasing in cAMP levels, we considered the partic-
ipation of other receptor that could mediate the production of
cAMP. Here we show that adenosine A2a receptors (A2aR) are
involved on IL-6 effect; additionally, we show the existence of a
complex signalling pathway that involves modulation of IL-6,
BDNF, A1R and A2aR levels resulting in the neuroprotection of
axotomized RGC.2. Materials and methods
2.1. Materials
IL-6, antibodies anti-IL-6 and anti-BDNF were purchased from
PeproTech (USA). Zm241385, CHA and CGS21680 came from Tocris
(UK). SQ22536 was bought from Enzo Life Science (Switzerland).
H89 came from BIOMOL Research Laboratories (USA). Bovine
serum albumin (BSA), anti p-CREB antibody and anti, anti actin
antibody, A2aR antibody came from Santa Cruz (USA). Anti A1R
antibody was bought from CHEMICON (USA). Anti rabbit and anti
mouse HRP conjugated antibodies were purchased from Bio-Rad
(USA). Medium 199 and trypsin were purchased from Gibco
(USA). Petri dishes were bought from TPP (Switzerland). Penicillin
G, streptomycin sulphate, L-glutamine, poly-L-ornithine, horserad-
ish peroxidase (HRP), tetramethylbenzidine, sodium nitroprusside
and dimethylsulphoxide (DMSO) were obtained from Sigma (USA).
Paraformaldehyde, glutaraldehyde, glycine and methanol were
bought from J.T. Baker (USA). Entellan was supplied by Merck
(Germany).2.2. Methods
2.2.1. Retrograde labelling of retinal ganglion cells
Lister Hooded rats were anaesthetized by hypothermia within
the ﬁrst 24 h after birth and 1.0 lL of a 30% HRP solution in 2%
DMSO was injected into each superior colliculus and the animal
was kept for about 16 h. All procedures using animals were
approved by the local committee for animal care and experimenta-
tion (CEPA-projects #00196-10).2.2.2. Cell culture
Primary cultures were prepared using procedures described
elsewhere [12,13]. The animals were killed by decapitation and
their eyes were removed. The retina was dissected in a calcium-
and magnesium-free balanced salt solution (CMF) containing
100 lg/mL streptomycin + 100 U/mL penicillin. The retinae were
incubated in CMF containing 0.1% trypsin for 16 min at 37 C.
The trypsin was inhibited by adding culture medium with 5% of
fetal calf serum (FCS). Tissue was then resuspended in complete
medium (culture medium supplemented with 2 mM glutamine,
100 lg/ml streptomycin, 100 U/mL penicillin and 5% FCS) and
mechanically dissociated using a Pasteur pipette. Cultures were
then incubated (density of 105 cells/cm2) in plates previously trea-
ted with poly-L-ornithine and kept in a humidiﬁed atmosphere of
5% CO2 and 95% air at 37 C for different timeframes. We also
tested the effect of the vehicles used for drug dilution and con-
cluded that they did not inﬂuence the survival of RGC (data not
shown).2.2.3. Identiﬁcation of RGC in culture
According to the protocol of Mesulan [30] cells were ﬁxed after
4 or 48 h in vitro with a mixture of 1% paraformaldehyde and 2%
glutaraldehyde and 0.1 M Sodium phosphate buffer for 5 min,
washed in phosphate buffer and then reacted with tetramethyl-
benzidine and H2O2. After the reaction, coverslips were washed
in 0.2 M Acetate buffer, dehydrated, immersed brieﬂy in xylene
and mounted in Entellan.2.2.4. Presentation of data and statistical analysis
The number of RGC on each coverslip was evaluated by count-
ing 1/20 of the total area using an Olympus microscope at a mag-
niﬁcation of 400 under bright ﬁeld. This quantiﬁcation was
performed using a double-blind process to minimise the inﬂuence
of the researcher on the experimental results. As an internal con-
trol for the variable percentage of ganglion cells labelled with
HRP in distinct experiments, the number of labelled cells at 4 h
in culture was taken as 100% (i.e. control). The results were
reported as percentages of the control. All data were expressed
as mean ± standard error of the mean from experiments performed
in duplicate or triplicate and each experiment was repeated at least
three times. The overall statistical signiﬁcance was ﬁrst obtained
by one-way analysis of variance (ANOVA). Statistical signiﬁcance
of all pairs of multiple groups of data was assessed by Newman–
Keuls comparison test. A value of P < 0.001 was considered
signiﬁcant.2.2.5. Western blot
Cells were scraped off the dishes in sample buffer and the mate-
rial boiled for 10 min. Total amount of protein in each sample was
determined using the Bradford reagent [31], with BSA as standard.
Samples containing 60 lg protein were submitted to 10%
SDS–PAGE gel electrophoresis and the proteins transferred to PVDF
membranes which were incubated overnight with the antibody,
washed, incubated with peroxidase-conjugated anti-rabbit
secondary antibody and revealed by Luminata (Millipore) chemilu-
minescence. Actin was used as a load control. The program ImageJ
was used to quantiﬁcate all the blots.2.2.6. Elisa
Measurements of IL-6 were done on cell-free medium superna-
tants using ELISA kits, in accordance with the manufacturer’s
























































































































































































Fig. 1. A – SQ22536 blocks the effect of IL-6 on the survival of RGC. CT – Control; SQ22536 – 9-(tetrahydro-2-furyl)adenine = Adenylyl cyclase inhibitor; IL-6 – Interleukin-
6. Data are presented as mean ± SEM (n = 6–10), P < 0.001 compared to control 48 h. B – Zm241385 blocks the effect of IL-6 on the survival of RGC. CT – Control; Zm241385
– 4-(2-[7-amino-2-{2-furyl}{1,2,4}triazolo{2,3-a}-{1,3,5}triazin-5-yl-amino]ethyl)phenol) – A2aR antagonist; IL-6 = Interleukin 6. Data are presented as mean ± SEM (n = 5–
12), P < 0.001 compared to control 48 h. C – CGS21680 induces an increase on the survival of RGC.CT – Control; CGS21680 – 3-[4-[2-[ [6-amino-9-[(2R,3R,4S,5S)-5-
(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid = A2aR agonist. Data are presented as mean ± SEM (n = 5–6), P < 0.001 compared
to control 48 h. D – SQ22536 blocks the effect of CGS21680 on RGC. CT – Control; SQ22536 – 9-(tetrahydro-2-furyl)adenine = Adenylcyclase inhibitor; CGS241385 – 3-[4-[2-
[ [6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid = A2aR agonist, (6–12). E – H89 blocked the
effect of CGS21680 on RGC. CT – Control; H89 – 5-isoquinolinesulfonamide, 2HCl = Protein Kinase A inhibitor; CGS241385 – 3-[4-[2-[ [6-amino-9-[(2R,3R,4S,5S)-5-
(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid = A2aR agonist. Data are presented as mean ± SEM (n = 6–10), P < 0.001



























































































































Fig. 2. A – phospho-CREB levels. CT – Control; CGS241385 – 3-[4-[2-[ [6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-
yl]amino]ethyl]phenyl]propanoic acid – A2aR agonist. Data are presented as mean ± SEM (n = 3), P < 0.001 compared to control 48h. B – Antibody anti-BDNF blocked
the effect of CGS21680 on the survival of RGC. CT – Control; CGS241385 – 3-[4-[2-[ [6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-
yl]amino]ethyl]phenyl]propanoic acid = A2aR agonist. Anti-BDNF 0.125 lg/mL. Data are presented as mean ± SEM (n = 7–9), P < 0.001 compared to control 48 h. C – BDNF
levels after A2aR activation for 45 min. CT = Control; CGS241385 – 3-[4-[2-[ [6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-
yl]amino]ethyl]phenyl]propanoic acid = A2aR agonist. Data are presented as mean ± SEM (n = 3), P < 0.001 compared to control 45 min. D – BDNF levels after A2aR
activation for 48 h. CT = Control; CGS241385 – 3-[4-[2-[ [6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propa-
noic acid = A2aR agonist. Data are presented as mean ± SEM (n = 7–9), P < 0.001 compared to control 48 h.
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3.1. Adenosine A2aR are involved on IL-6 effect
During our effort to better understand the mechanism by which
IL-6 increases the survival of RGC we investigated adenylyl cyclase
activity. Fig. 1A shows that after treatmentwith SQ22536, a selective
inhibitor of adenylyl cyclase activity, the IL-6 effect was abolished.
This result leaded us to investigate the involvement of A2aR in the
trophic effect of IL-6 on RGC. Therefore, we treated cultures with
IL-6 for 48 h in the presence of A2aR antagonist, ZM241385 (ZM),
and observed a complete blockade of IL-6 effect (Fig. 1B). Accord-
ingly, when cultures were treated with an A2aR agonist
(CGS21680) the RGC survival increased (Fig. 1C). Furthermore, cells
were treated with CGS21680 in the presence of an adenyl cyclase
inhibitor (Fig. 1D). As expected, the effect of CGS21680 was com-
pletely blocked. Also, following the inhibition of protein kinase A
(PKA) by 1 lM H89 the effect of CGS21680 was abolished (Fig. 1E).
3.2. A2aR activation modulates BDNF
Initially cultures were treated with CGS21680 for 45 min or
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Fig. 3. A – Anti-IL-6 antibody blocks the effect of both CHA and CGS21680. CT =
[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]ph
mean ± SEM (n = 6–9), P < 0.001 compared to control 48 h. B – IL-6 increases A2aR lev
presented as mean ± SEM (n = 3), P < 0.001 compared to control 24 h. C – IL-6 increases A
are presented as mean ± SEM (n = 3), P < 0.001 compared to control 24 h. D – IL-6 increas
Data are presented as mean ± SEM (n = 3), P < 0.001 compared to control 48 h. D –
mL = Interleukin-6. Data are presented as mean ± SEM (n = 3), P < 0.001 compared to conthat treatment with CGS21680 for 48 h induced an increase (63%)
in phospho-CREB levels. As phospho-CREB is a transcription factor
related to BDNF production, we investigated the involvement of
BDNF in the trophic effect of CGS21680 on RGC [34]. Fig. 2B dem-
onstrates that the effect of CGS21680 was completely abolished by
the presence of the antibody anti-BDNF. Following, we analysed
the levels of BDNF after CGS21680 treatment. Our results show
that treatment with CGS21680 for 45 min did not increase the lev-
els of BDNF (Fig. 2C). However, after 48 h CGS21680 treatment the
levels of BDNF increased 35% (Fig. 2D).
3.3. Interleukin-6 plays an important role on A1 and A2aR expression
To conﬁrm that the effect of A1 and A2a receptors activation on
RGC survival was mediated by IL-6 we neutralized it in the extra-
cellular medium. Fig. 3A shows that in the absence of extracellular
IL-6 both CHA and CGS21680 showed no trophic effect. In addition,
the A1 and A2aR expressions were analysed after treatment with
IL-6. Fig. 3B shows that after treatment with IL-6 for 24 h, the lev-
els of A2aR signiﬁcantly increased 85% and the levels of A1R
decreased 48% (Fig. 3C). However, after IL-6 treatment for 48 h
the levels of A2aR decreased 24% (Fig. 3D) and the levels of A1R
















































Control; CHA – N(6)-cyclohexyladenosine; CGS241385 – 3-[4-[2-[ [6-amino-9-
enyl]propanoic acid = A2aR agonist. Anti-IL-6 0.2 lg/mL; Data are presented as
els after 24 h of treatment. CT = Control; IL-6 50 ng/mL = Interleukin-6. Data are
1R levels after 24 h of treatment. CT = Control; IL-6 50 ng/mL = Interleukin-6. Data
es A2aR levels after 48 h of treatment. CT = Control; IL-6 50 ng/mL = Interleukin-6.
IL-6 increases A1R levels after 48 h of treatment. CT = Control; IL-6 50 ng/
trol 48 h.
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intra and extracellular IL-6
The release of IL-6 was analysed after treatment with either
CGS21680 or CHA for 48 h. Fig. 4A shows that A2aR activation
increases 142% IL-6 release (291 lg/mL). On the contrary, A1R acti-
vation signiﬁcantly decreased in 70% the release of the cytokine
(26 lg/mL). The expression of IL-6 was also analysed after A1
and A2aR activation. Unexpectedly, as shown in Fig. 4B, CHA treat-
ment for 48 h increased 94% IL-6 expression. As expected, Fig. 4C
shows, that A2aR activation increased in 46% IL-6 expression. The
IL-6 release was also analysed after treatment with BDNF for
48 h. Fig. 4D shows that BDNF also signiﬁcantly increased in 83%
the IL-6 expression (99 lg/mL).4. Discussion
Earlier results from our group showed that IL-6 increase the
survival of RGC [12,13] by inducing adenosine release and, as a
consequence, A1R activation [13]. During our efforts to elucidate
the signalling pathway triggered by L-6, the importance of adenylyl
cyclase activation was observed. Since A1R is well known for its
capacity to inhibit the adenyl cylcase [32], the participation of
other adenosine receptors on IL-6 trophic effect was considered.
In culture of avian, long-term activation of A2aR blocked gluta-
mate excitotoxicity on retinal neurons [21]. A2aR can also modu-
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Fig. 4. A – Adenosine A1 and A2aRmodulates IL-6 release. CT = Control; CHA – N(6)-cyc
5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoi
compared to control 48 h. A – Adenosine A1 receptor activation increases IL-6 levels.
mean ± SEM (n = 3), P < 0.001 compared to control 48 h. B – Adenosine A2a receptor a
[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]ph
P < 0.001 compared to control 48 h. C – BDNF treatment increase the release of IL-6. Ddeprivation [29]. In agreement with those ﬁndings, our treatment
of cultures with IL-6 in the presence of Zm241385 (A2a antagonist)
did not increase the RGC survival. Furthermore, cultures that
received treatment with A2a agonist CGS21680 presented an
increase in RGC survival similar to that observed following IL-6
treatment. Additionally, cultures treated with CGS21680 showed
similar morphologic characteristics to those treated with IL-6 (data
not shown). In agreement with the literature, the inhibition of
cAMP production completely inhibited CGS216801 trophic effect.
This result indicates that the intracellular pathway involved in
the trophic effect of CGS216801 is the classical pathway elicited
by A2a receptors activation [16].
The cAMP-signalling cascade classically involves Protein Kinase
A (PKA) activation [32]. In accordance to the literature CGS21680
effect was blocked after inhibition of PKA with H89, suggesting
PKA involvement in A2aR signalling [16,32,33]. PKA is classically
involved with CREB (cAMP responsive element-binding protein)
phosphorilation [34]. Therefore the levels of phospho-CREB were
analysed after treatment with CGS21680.
In the last few years, many authors have demonstrated the exis-
tence of a crosstalk between A2aR and BDNF. The literature shows
that not only A2aR are involved in the mechanism of TrkB recep-
tors transactivation, but they also modulate the effect of BDNF
on synaptic transmition [35]. In agreement with the literature,
the effect of CGS21680 was abolished in the presence of anti-BDNF
antibody. Previous data from our group showed that after 45 min
of IL-6 treatment BDNF levels increased and that treatment for




















CT      CHA
lohexyladenosine = A1R agonist; CGS241385 – 3-[4-[2-[ [6-amino-9-[(2R,3R,4S,5S)-
c acid = A2aR agonist. Data are presented as mean ± SEM (n = 10–14), P < 0.001
CT – Control; CHA – N(6)-cyclohexyladenosine = A1R agonist. Data are presented as
ctivation increases IL-6 levels. CT = Control; CGS241385 – 3-[4-[2-[ [6-amino-9-
enyl]propanoic acid = A2aR agonist. Data are presented as mean ± SEM (n = 3),
ata are presented as mean ± SEM (n = 6–8), P < 0.001 compared to control 48 h.
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onstrate that the activation of A2a receptor for 48 h, but not for
45 min, increased phospho-CREB and BDNF levels. This result
suggests that in the signalling pathway triggered by IL-6 the
A2aR activation comes ﬁrst followed by A1R activation. This was
conﬁrmed by the treatment with IL-6 that decreased A1R and
increased A2aR levels after 24 h. Additionally, after 48 h of treat-
ment, the A1R levels increased whilst A2aR expression decreased.
Together, these results suggest that both A2aR and A1R play an
important role on BDNF levels and that IL-6 modulates BDNF levels
through the regulation the adenosine A1 and A2aR expression.
Torres and Araujo (2001) showed that in order to increase the
survival of RGC, IL-6 must be present in cultures for the full 48 h
[12]. In agreement with the literature we showed that both CHA
and CGS21680 effects were neutralized in cultures treated with
anti-IL-6 antibody. Although the levels of IL-6 increased after both
A1 and A2aR stimulation, after treatment with CHA cultures
released low levels of IL-6 whereas after treatment with
CGS21680 the cultures released higher levels of IL-6. While further
studies are necessary, we suggest that the levels of IL-6 might be
crucial to adenosine receptor modulation and that the balance
between A1 and A2aR levels is related to the concentration of
IL-6 in the extracellular medium.
Data from literature often relate IL-6 to BDNF [13,36,37]. Here
we found that the increase in BDNF matches the extracellular pres-
ence of IL-6 and that BDNF releases IL-6. Based on this ﬁnding and
given the fact the CGS effect depends on BDNF, we may conclude
that the signalling pathways triggered by A2aR activation would
be inducing IL-6 release through a BDNF stimulus.
IL-6 has multiple actions in different cell systems and its effect
on RGC survival is not fully understood. Even if many questions
remain unanswered, the signalling pathway triggered by IL-6 has
shown to be promising in the treatment of diseases related to
RGC death. A problem is that it is not easy to use IL-6 in clinical
practice, since it can act as a pro-inﬂammatory cytokine inducing
side effects such as fever or even cell death [38]. One possible strat-
egy to tackle this problem is to use adenosine receptor agonists as
downstream activators of the IL-6 pathway. Since there is an A2aR
agonist already approved by the FDA for clinical practice [39], stud-
ies that relate adenosine receptors with IL-6 trophic effect might
guide us to new pharmacological approaches that may beneﬁt
several patients who suffer diseases related to RGC death.
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